{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T05:41:22Z","timestamp":1698385282698},"reference-count":11,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2008,6,28]],"date-time":"2008-06-28T00:00:00Z","timestamp":1214611200000},"content-version":"vor","delay-in-days":4715,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Gastro and Hepatol"],"published-print":{"date-parts":[[1995,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Roxatidine acetate, a new H<jats:sub>2<\/jats:sub> receptor antagonist, was compared with ranitidine in the treatment of duodenal ulcers in a double\u2010blind multicentre study. Eighty\u2010four patients with endoscopically proven duodenal ulcer were randomized to receive 150 mg roxatidine acetate or 300 mg ranitidine at bedtime. Repeat endoscopy was performed after 4 weeks (25\u201333 days) and if the ulcer had not healed, another endoscopy was performed after a further 4 weeks of treatment. Using per protocol analysis 73.6% of ulcers treated with roxatidine healed at 4 weeks compared to 72.2% of ulcers treated with ranitidine (<jats:italic>P<\/jats:italic>=NS). The healing rates at 8 weeks were 92% with roxatidine and 83.3% with ranitidine (<jats:italic>P<\/jats:italic>=NS). Using equivalence tests, the healing rate of roxatidine was found to be equivalent to that of ranitidine within a 20% region. Roxatidine users took significantly less antacids than ranitidine users (<jats:italic>P<\/jats:italic> &lt; 0.05). There were no significant adverse effects due to roxatidine or ranitidine. Roxatidine is a safe effective drug in the treatment of duodenal ulcers with a healing rate comparable to that of ranitidine.<\/jats:p>","DOI":"10.1111\/j.1440-1746.1995.tb01587.x","type":"journal-article","created":{"date-parts":[[2008,3,10]],"date-time":"2008-03-10T23:42:13Z","timestamp":1205192533000},"page":"379-382","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Roxatidine versus ranitidine in the treatment of duodenal ulcers: A randomized double\u2010blind controlled multicentre study in Singapore"],"prefix":"10.1111","volume":"10","author":[{"given":"KM","family":"FOCK","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JY","family":"KANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HS","family":"NG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TM","family":"NG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KA","family":"GWEE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CC","family":"LIM","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,6,28]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/236385a0"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198800353-00015"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.26.10.1038"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01537099"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780091208"},{"key":"e_1_2_1_7_2","first-page":"847","article-title":"A multicentre, double\u2010blind, placebo\u2010controlled comparison of nocturnal roxatidine in the treatment of active duodenal ulcer disease","volume":"87","author":"Gillinsky NH","year":"1992","journal-title":"Am. J. Gastroenterol."},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1991.tb00031.x"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198800353-00017"},{"key":"e_1_2_1_10_2","first-page":"2","article-title":"Review of the clinical efficacy and safety of a new H2 antagonist in the treatment of peptic ulcer disease in Korea","volume":"1","author":"Lee YS.","year":"1990","journal-title":"Gastroenterol. Conspectus"},{"key":"e_1_2_1_11_2","first-page":"144","volume-title":"Drugs in Gastroenterology","author":"Canali A.","year":"1991"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-111-1-7"}],"container-title":["Journal of Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1746.1995.tb01587.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1746.1995.tb01587.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T20:15:01Z","timestamp":1698351301000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1746.1995.tb01587.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,8]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1995,8]]}},"alternative-id":["10.1111\/j.1440-1746.1995.tb01587.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1746.1995.tb01587.x","archive":["Portico"],"relation":{},"ISSN":["0815-9319","1440-1746"],"issn-type":[{"value":"0815-9319","type":"print"},{"value":"1440-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,8]]},"assertion":[{"value":"2008-06-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}